Loading...
Market
Number of combination therapy trials for Eli Lilly's PI3Kα inhibitor by end of 2025?
2
Resolution / Starting Odds
1 trial • 25%
2 trials • 25%
3 trials • 25%
More than 3 trials • 25%
Eli Lilly's clinical trial announcements
Story
Eli Lilly to Acquire Scorpion's PI3Kα Cancer Drug for Up to $2.5 Billion Including $1 Billion Upfront
Jan 13, 2025, 02:41 PM
Eli Lilly and Company has announced an agreement to acquire Scorpion Therapeutics' mutant-selective PI3Kα inhibitor program targeting advanced solid tumors, including breast cancer. The deal is worth up to $2.5 billion, comprising a $1 billion upfront payment and up to $1.5 billion in performance-based milestones. The PI3Kα inhibitor is currently in Phase 1/2 clinical trials, being evaluated as monotherapy or in combination therapies, with preliminary data showing an objective response rate of 23%. Lilly's Chief Scientific Officer, Dan Skovronsky, commented that the acquisition "checked all the boxes" for the company's strategic objectives, as it aims to expand its oncology pipeline with innovative clinical programs.
View original story
Similar markets
Three or more • 25%
Two • 25%
None • 25%
One • 25%
5 or more new partnerships • 25%
1-2 new partnerships • 25%
0 new partnerships • 25%
3-4 new partnerships • 25%
11-15 trials • 25%
0-5 trials • 25%
6-10 trials • 25%
More than 15 trials • 25%
Two • 25%
None • 25%
Three or more • 25%
One • 25%
Negative results • 25%
Trial extended • 25%
Inconclusive results • 25%
Positive results • 25%
None • 25%
Three or more • 25%
Two • 25%
One • 25%
20-30% • 25%
More than 30% • 25%
Less than 10% • 25%
10-20% • 25%
Positive results leading to Phase 2 • 25%
Neutral results requiring further study • 25%
Negative results halting development • 25%
Other outcome • 25%
Positive efficacy, but safety concerns • 25%
Negative efficacy and safety concerns • 25%
Positive efficacy and safety results • 25%
Negative efficacy, but good safety • 25%
Trial stopped early for efficacy • 25%
Significant survival improvement • 25%
No significant survival improvement • 25%
Trial stopped early for safety concerns • 25%